No significant differences were found in SNOT between macrolide-treated and control groups at 8, 12, and 24 weeks. (A) In cohort trials, there was a significant difference in SNOT scores between the macrolide-treated and control groups (P=0.009) at the 8-week visit. In contrast, there was no significantly different in the RCTs subgroup (P=0.38). (B) No significant differences were found in SNOT scores between macrolide-treated and control groups in RCTs (P=0.34) or cohort trials subgroups (P=0.07) at 12-week visit. (C) No significant differences existed in SNOT scores between macrolide-treated and control groups in RCTs (P=0.28) or cohort trials (P=0.05) at 24-week visit. SNOT, Sino-Nasal Outcome Test; RCTs, randomised clinical trials.